AGC Biologics, a global company involved in clinical and commercial development and manufacturing of therapeutic proteins, announced yesterday that it has named Kasper Moller as its new chief technical officer.
Moller will report to Patricio Massera, chief executive officer.
Moller joined AGC Biologics in 2006 as a scientist at the Copenhagen facility and has held the positions of principal scientist (2007) and department manager (2008) within Process Development. Beginning in 2010, Kasper led the Upstream Process Development teams and in 2011, he led process characterisation and validation activities. In 2013 - 2014, Kasper was appointed vice president of Process Development and in 2014 – 2017, Kasper was appointed vice president of Manufacturing. He has most recently served as the site head for AGC Biologics' Copenhagen facility and his role was expanded to include oversight of the Heidelberg, Germany site as well as Global Supply Chain Management and Global IT.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business